PRAME, as its name implies, was first identified in melanoma cells and has been demonstrated to increase metastatic potential through repression of RAS, promotion of EMT, and promotion of an immunologically “cold” tumor microenvironment (TME) [4,8,17]. The gene discussed is PRAME; the disease is neoplasm.